GW Pharmaceuticals Plc
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to transforming the lives of patients with serious diseases through innovative medicines. The company focuses on neuroscience and oncology, developing life-changing medicines for people with limited or no options. With a diverse portfolio of marketed medicines and a growing pipeline, Jazz is committed to pioneering research and patient-centric solutions.
Industries
Nr. of Employees
medium (51-250)
GW Pharmaceuticals Plc
3170 Porter Dr., Palo Alto, California 94304
Products
Portfolio of marketed therapies for neuroscience and oncology
A set of marketed medicines addressing sleep disorders, epilepsy and oncology, plus therapies for select rare and complex diseases, distributed across multiple international markets.
Portfolio of marketed therapies for neuroscience and oncology
A set of marketed medicines addressing sleep disorders, epilepsy and oncology, plus therapies for select rare and complex diseases, distributed across multiple international markets.
Services
Assessment and execution of licensing, acquisition and partnership opportunities across preclinical to commercial-stage assets; post-transaction integration support.
Provision of medical information to healthcare professionals and management of adverse event reporting and product complaint processes internationally.
Design and conduct of interventional clinical trials, non-interventional studies and expanded access programs to evaluate safety and efficacy of investigational therapies.
Regional manufacturing and development operations to support clinical and commercial supply, including coordination with third-party manufacturers and logistics partners for distribution.
Services and governance frameworks to support alliance management, partner training, tools and tailored guidance for strategic collaborations.
Processing of privacy inquiries and state-level data subject requests (access, correction, deletion, limitation of use, revocation of consent) via formal request mechanisms and a designated privacy office contact.
Assessment and execution of licensing, acquisition and partnership opportunities across preclinical to commercial-stage assets; post-transaction integration support.
Provision of medical information to healthcare professionals and management of adverse event reporting and product complaint processes internationally.
Design and conduct of interventional clinical trials, non-interventional studies and expanded access programs to evaluate safety and efficacy of investigational therapies.
Regional manufacturing and development operations to support clinical and commercial supply, including coordination with third-party manufacturers and logistics partners for distribution.
Services and governance frameworks to support alliance management, partner training, tools and tailored guidance for strategic collaborations.
Processing of privacy inquiries and state-level data subject requests (access, correction, deletion, limitation of use, revocation of consent) via formal request mechanisms and a designated privacy office contact.
Expertise Areas
- Clinical trial management
- Oncology drug development
- Neuroscience drug development
- Rare disease therapeutics
Key Technologies
- Bispecific antibody engineering
- Targeted biologics
- Small-molecule drug discovery
- Cannabinoid science in therapeutics
News & Updates
Jazz Pharmaceuticals announced FDA approval for Modeyso™, the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma.
The company announced its Q2 2025 financial results and updated its financial guidance.
Deepening commitment to oncology with FDA-approved treatment bringing new hope for this aggressive cancer.
Importance of early identification and molecular diagnosis for treatment planning.
Exploring new strategies to extend impact of initial therapy in this difficult-to-treat cancer.
Jazz Pharmaceuticals announced FDA approval for Modeyso™, the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma.
The company announced its Q2 2025 financial results and updated its financial guidance.
Deepening commitment to oncology with FDA-approved treatment bringing new hope for this aggressive cancer.
Importance of early identification and molecular diagnosis for treatment planning.
Exploring new strategies to extend impact of initial therapy in this difficult-to-treat cancer.